Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech reported favorable exploratory analyses of paridiprubart, an anti-TLR4 monoclonal antibody, demonstrating a 32% relative reduction in 28-day mortality and a 23% reduction in major adverse kidney events at 30 days among patients with acute kidney injury (AKI) and respiratory distress. These findings extend previous Phase 3 results in A…